Sansure Biotech Inc Asset Resilience Ratio

Latest as of June 2026: 1.06%

Sansure Biotech Inc asset resilience ratio. Sansure Biotech Inc (688289) has an Asset Resilience Ratio of 1.06% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Sansure Biotech Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.

Liquid Assets

CN¥101.93 Million
≈ $14.92 Million USD Cash + Short-term Investments

Total Assets

CN¥9.64 Billion
≈ $1.41 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of Sansure Biotech Inc (2019–2025)

Asset resilience ratio of Sansure Biotech Inc from 2019 to 2025. This chart shows how Sansure Biotech Inc's Asset Resilience Ratio has changed over time. Read debt load of Sansure Biotech Inc for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Sansure Biotech Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Sansure Biotech Inc total assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥101.93 Million 1.06%
Total Liquid Assets CN¥101.93 Million 1.06%

Asset Resilience Insights

  • Limited Liquidity: Sansure Biotech Inc maintains only 1.06% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Sansure Biotech Inc Industry Peers by Asset Resilience Ratio

Compare Sansure Biotech Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Imeik Technology Development Co
SHE:300896
Medical Instruments & Supplies 26.02%
SciVision Biotech Inc
TW:1786
Medical Instruments & Supplies 6.42%
Ansell Ltd
AU:ANN
Medical Instruments & Supplies 7.53%
Nanosonics Ltd
AU:NAN
Medical Instruments & Supplies 46.84%
SDI Ltd
AU:SDI
Medical Instruments & Supplies 3.36%
Austco Healthcare Ltd
AU:AHC
Medical Instruments & Supplies 15.90%
Trajan Group Holdings Ltd
AU:TRJ
Medical Instruments & Supplies 0.29%
Osteopore Ltd
AU:OSX
Medical Instruments & Supplies 22.60%

Sansure Biotech Inc Asset Resilience Ratio by Year (2019–2025)

Sansure Biotech Inc asset resilience ratio by year from 2019 to 2025. The table below shows the annual Asset Resilience Ratio data for Sansure Biotech Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 1.65% CN¥157.10 Million
≈ $22.99 Million
CN¥9.53 Billion
≈ $1.39 Billion
+0.03pp
2024-12-31 1.62% CN¥139.67 Million
≈ $20.44 Million
CN¥8.60 Billion
≈ $1.26 Billion
-4.86pp
2023-12-31 6.49% CN¥548.28 Million
≈ $80.23 Million
CN¥8.45 Billion
≈ $1.24 Billion
-20.23pp
2022-12-31 26.72% CN¥2.45 Billion
≈ $358.69 Million
CN¥9.17 Billion
≈ $1.34 Billion
-2.14pp
2021-12-31 28.86% CN¥2.05 Billion
≈ $299.46 Million
CN¥7.09 Billion
≈ $1.04 Billion
-0.49pp
2020-12-31 29.36% CN¥1.60 Billion
≈ $234.31 Million
CN¥5.45 Billion
≈ $798.15 Million
+19.03pp
2019-12-31 10.32% CN¥66.33 Million
≈ $9.71 Million
CN¥642.47 Million
≈ $94.01 Million
--
pp = percentage points

About Sansure Biotech Inc

SHG:688289 China Medical Instruments & Supplies
Market Cap
$1.33 Billion
CN¥9.08 Billion CNY
Market Cap Rank
#7455 Global
#1597 in China
Share Price
CN¥15.79
Change (1 day)
-0.82%
52-Week Range
CN¥13.87 - CN¥22.12
All Time High
CN¥81.40
About

Sansure Biotech Inc. researches and develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. It offers nucleic acid and multiple nucleic acid diagnostic kits for coronavirus, CoV-2, influenza virus, and respiratory syncytial virus; DNA fluorescence and nucleic acid diagnostic kits for respiratory tract infections, HPV infections, and reproductive tr… Read more